- Tesaglitazar
Drugbox
IUPAC_name = (2"S")-2-Ethoxy-3- [4- [2-(4-methylsulfonyloxyphenyl)ethoxy] phenyl] propanoic acid
CAS_number = 251565-85-2
ATC_prefix =
ATC_suffix =
PubChem = 208901
DrugBank =
smiles = CCO [C@@H] (CC1=CC=C(C=C1)OCCC2=CC=C(C=C2)OS(=O)(=O)C)C(=O)O
C=20|H=24|O=7|S=1
molecular_weight = 408.46
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =Tesaglitazar is a
peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ, proposed fortype 2 diabetes .cite journal |author=Wilding JP, Gause-Nilsson I, Persson A |title=Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes |journal=Diab Vasc Dis Res |volume=4 |issue=3 |pages=194–203 |year=2007 |pmid=17907109 |doi=10.3132/dvdr.2007.040]The drug had completed several phase III clinical trials,cite web | url = http://www.astrazenecaclinicaltrials.com/ncmprintchapter.aspx?type=article¶m=520974 | title = GALIDA™ (tesaglitazar) Clinical Trial Report Summaries | accessdate = 2008-03-17 | author = | authorlink = | coauthors = | date = | format = | work = | publisher = AstraZeneca | pages = | language = | archiveurl = | archivedate = | quote = ] however in May, 2006
AstraZeneca announced that it had discontinued further development.cite web | url = http://www.astrazeneca.com/pressrelease/5240.aspx | title = AstraZeneca Discontinues Development of GALIDA (tesaglitazar) | accessdate = 2008-03-17 | author = | authorlink = | coauthors = | date = 2006-05-04 | format = | work = | publisher = AstraZeneca | pages = | language = | archiveurl = | archivedate = | quote = ]References
Wikimedia Foundation. 2010.
